| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000007982 |
| Receipt No. | R000009397 |
| Official scientific title of the study | A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects. |
| Date of disclosure of the study information | 2012/05/25 |
| Last modified on | 2016/04/09 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects. | |
| Title of the study (Brief title) | Drug interaction study between Midazolam and Anchu-san. | |
| Region |
|
|
| Condition | ||
| Condition | Japanese healthy male | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The pilot study that previously conducted (UMIN ID:000006655) suggested that 7 days oral Anchu-san administration would affect on PK of oral Midazolam dose. Therefore the verification study will be conducted with increased number of study subjects. This is a verification study to investigate the effects of the 6 days Anchu-san multiple dose (7.5/day) on the pharmacokinetics of oral administration of midazolam (7.5mg) in Japanese healthy male subjects.
The pharmacodynamic interaction between midazolam and Anchu-san will also be investigated. |
| Basic objectives2 | PK,PD |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The pharmacokinetic parameters of midazolam in serum (AUC 0-10, Cmax, t1/2, tmax). |
| Key secondary outcomes | The sedative action after midazolam oral administration: VAS
Safety assessment (pulse oximeter, vital measurement, adverse event) |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Midazolam single oral administration | |
| Interventions/Control_2 | Midazolam single oral administration after 6 days Anchu-san (7.5g/day) dose | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1) Age: 20 - 45 years old at the time of informed consent
2)Sex: male 3) Subjects are competent to consent, keep the rules of the study and are able to report self condition. 4) Subjects who are judged eligible by the investigator in several series of medical check conducted prior to study. |
|||
| Key exclusion criteria | 1) Subjects who have an inappropriate clinical history for efficacy and safety assessment in the study (such as drug abuse, alcoholism, and the disease of heart, liver, kidney, lungs, eye, blood etc) and who is taking any drugs (including health supplements).
2) Any history for drug allergy 3) Subjects who are taking in too much alcohol (those who cannot maintain the abstains from alcohol during study period) 4) Subjects within three months after the participation to other clinical trials 5) Subjects who are inadequate for enrollment judged by the investigator. |
|||
| Target sample size | 6 | |||
| Research contact person | |
| Name of lead principal investigator | Naoki Uchida MD, PhD |
| Organization | Showa University School of Medicine |
| Division name | Department of Clinical Pharmacology |
| Address | 1-5-8 Hatanodai Shinagawa-ku Tokyo 142-8555 |
| TEL | 03-3784-8128 |
| nuchida@med.showa-u.ac.jp | |
| Public contact | |
| Name of contact person | Hirokazu Toshima MD |
| Organization | Showa University School of Medicine |
| Division name | Department of Clinical Pharmacology |
| Address | 1-5-8 Hatanodai Shinagawa-ku Tokyo 142-8555 |
| TEL | 03-3784-8128 |
| Homepage URL | |
| showa_northern@yahoo.co.jp | |
| Sponsor | |
| Institute | Showa University School of Medicine Department of Clinical Pharmacology |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 昭和大学臨床薬理研究センター(東京都)
Showa University Clinical Trial Center for Clinical Pharmacology (Tokyo) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | This study was performed in 7 subjects. No adverse event was observed during the study in all subjects.
Mean value of PK parameter of plasma Midazolam are as follows; Pre-dose of Anchu-san Cmax:64.99+/-18.61ng/mL, AUC:192.59+/-78.13ng*hr/mL After 7 days Anchu-san dose Cmax:88.66+/-16.37ng/mL, AUC:249.06+/-72.84ng*hr/mL No difference was observed in VAS scale between pre- and post- Anchu-san dose. It was suggested that 7 days oral Anchu-san administration would affect on PK of oral Midazolam dose. J. Showa Med Assoc.(in print) |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000009397 |